Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for Viyash Scientific's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:VIYASH vs ZTS, UTHR: Buyback Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Viyash Scientific's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viyash Scientific Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Viyash Scientific's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Viyash Scientific's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viyash Scientific (NSE:VIYASH) has a Buyback Yield % of -1.42 as of Jul. 14, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Viyash Scientific and its competitors. According to the industry distribution chart, Viyash Scientific ranks #162 out of 290 companies in the Drug Manufacturers industry, placing it in the top 55.9%.
Is Viyash Scientific's Buyback Yield % too high?
Viyash Scientific's current Buyback Yield % is -1.42. Based on the distribution chart, Viyash Scientific ranks #162 out of 290 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Viyash Scientific has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viyash Scientific's Buyback Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Viyash Scientific ranks #162 out of 290 companies for Buyback Yield %. This places Viyash Scientific in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Viyash Scientific and its competitors. Viyash Scientific's current Buyback Yield % is -1.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viyash Scientific stock overvalued right now?
Based on GuruFocus' analysis, Viyash Scientific (NSE:VIYASH) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹172.27, compared to a current price of ₹284.35 — trading 65.1% above its estimated fair value. The current Buyback Yield % is -1.42. Viyash Scientific's overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Viyash Scientific (NSE:VIYASH), the current Buyback Yield % is -1.42 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viyash Scientific (NSE:VIYASH) Overvalued in 2026?
Based on GuruFocus' analysis, Viyash Scientific stock appears to be overvalued.
The current stock price of ₹284.35 is trading 65.1% above its estimated GF Value™ of ₹172.27.
GuruFocus considers Viyash Scientific to be Significantly Overvalued.
Key valuation signals for NSE:VIYASH:
Buyback Yield %: -1.42
GF Value™: ₹172.27 vs. price of ₹284.35 (65.1% above fair value)
No single metric tells the full story. See the NSE:VIYASH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viyash Scientific Ltd is a pharmaceutical company with activities spanning formulations, active pharmaceutical ingredients (APIs), and intermediates. It is focused on research and development infrastructure for APIs and formulations. Its product portfolio spans several therapeutic areas, including ARV, cardiovascular, central nervous system, analgesics, antibiotics, antihistamines, diabetes, gastrointestinal, anticoagulants, and oncology.
73GF Score
Get the complete analysis for NSE:VIYASH
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:VIYASH has been successfully added to your 
